Literature DB >> 10094939

Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression.

C Degott1, E S Zafrani, P Callard, B Balkau, R E Poupon, R Poupon.   

Abstract

The semiquantitative histopathological analysis of the liver biopsies obtained before and after 4 years of ursodeoxycholic acid (UDCA) therapy in a cohort of primary biliary cirrhosis (PBC) patients is reported. The relationships between elementary histological lesions before treatment and their progression under therapy were assessed. At baseline, two independent groups of lesions, each of which participate in the development of fibrosis, were individualized, i.e., florid bile duct lesions and ductopenia on one hand and lymphocytic piecemeal necrosis, ductular proliferation, and lobular necroinflammatory changes on the other hand. Four years of UDCA therapy were associated with a significant decrease in the prevalence of florid interlobular bile duct (ILBD) lesions, of epithelioid granuloma (P <.001) without any aggravation in the severity of bile duct paucity. Lobular inflammation and necrosis markedly improved (P <.001) whereas the degree of severity of the lymphocytic piecemeal necrosis and ductular proliferation at entry and at 4 years were similar. Worsening of fibrosis was observed in 14 patients (12 of them had a one grade progression) whereas stabilization was noted in 30 of the remaining patients. Severity of both the lymphocytic piecemeal necrosis and lobular inflammation and necrosis at entry was significantly associated with the progression of fibrosis. The results suggest that UDCA therapy influences the process leading to bile duct destruction. Patients with severe lymphocytic piecemeal necrosis and lobular inflammation may need additional therapeutic intervention because they have increased risk of fibrosis progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094939     DOI: 10.1002/hep.510290444

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases.

Authors:  Takashi Himoto; Hirohito Yoneyama; Kazutaka Kurokohchi; Michio Inukai; Hisashi Masugata; Fuminori Goda; Reiji Haba; Seishiro Watanabe; Shoichi Senda; Tsutomu Masaki
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

2.  Primary biliary cirrhosis: Renaming primary biliary cirrhosis-clarity or confusion?

Authors:  Palak J Trivedi; Gideon M Hirschfield
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-11-10       Impact factor: 46.802

3.  Timing and risk factors of hepatectomy in the management of complications following laparoscopic cholecystectomy.

Authors:  J Li; A Frilling; S Nadalin; C E Broelsch; M Malago
Journal:  J Gastrointest Surg       Date:  2011-11-09       Impact factor: 3.452

Review 4.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

Review 5.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 6.  Combination antiretroviral studies for patients with primary biliary cirrhosis.

Authors:  Ellina Lytvyak; Aldo J Montano-Loza; Andrew L Mason
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 7.  Primary biliary cirrhosis: new thoughts on pathophysiology and treatment.

Authors:  Andrew Mason; Sateesh Nair
Journal:  Curr Gastroenterol Rep       Date:  2002-02

8.  Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.

Authors:  Ryuichi Kita; Seigo Takamatsu; Toru Kimura; Hiroyuki Kokuryu; Yukio Osaki; Naomi Tomono
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

9.  A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.

Authors:  Masao Omata; Haruhiko Yoshida; Joji Toyota; Eiichi Tomita; Shuhei Nishiguchi; Norio Hayashi; Shiro Iino; Isao Makino; Kiwamu Okita; Gotaro Toda; Kyuichi Tanikawa; Hiromitsu Kumada
Journal:  Gut       Date:  2007-06-15       Impact factor: 23.059

10.  The value of antinuclear antibodies in primary biliary cirrhosis.

Authors:  Lixia Gao; Xinping Tian; Bin Liu; Fengchun Zhang
Journal:  Clin Exp Med       Date:  2008-04-03       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.